Meet our team at booth #207 during the 21st annual meeting of the American Society of Gene & Cell Therapy (ASGCT) in Chicago (Illinois, United Sates), May 16-19th, 2018.
Our products for gene & cell therapy
PEIpro®-HQ is a highly qualified grade of PEIpro® reagent, especially developed for the production of clinical batches of recombinant proteins, antibodies or viral vectors. This reagent is a linear Polyethylenimine (PEI) based transfection reagent widely used for the development of large-scale bioproduction processes in adherent or suspension HEK-293 or CHO cells grown in synthetic serum-free media. The PEIpro®-HQ grade is supplied with appropriate Quality Controls and documentation allowing its use as a qualified raw material in GMP processes for the manufacturing of clinical batches of therapeutic products. PEIpro®-HQ is a fully synthetic reagent free of any animal-origin components. PEIpro®-HQ is manufactured and formulated using a well-established and controlled manufacturing process, allowing the reproducible supply of remarkably high quality product meeting very stringent release specifications.
in vivo delivery of nucleic acids represents a novel promising approach for some medical applications such as gene and oligonucleotides therapy. in vivo-jetPEI®, a cationic polymer-based reagent, is a very powerful non-viral vector to safely and easily deliver nucleic acids in vivo, through different routes of administrations. It offers high performance in terms of efficiency, reproducibility and robustness. Nowadays, in vivo-jetPEI® is the most widely used chemical reagent to deliver gene in animals, and was selected as the delivery vector of choice in several drug development programs. For this purpose, Polyplus-transfection® offers a cGMP grade in vivo-jetPEI® which is manufactured in compliance with applicable European Commission (EC) guide to Good Manufacturing Practices (GMP) and FDA requirements for clinical trials phase I to III. This reagent is used worldwide for a growing number of therapies based on nucleic acid delivery.
- Session Date/Time: Wednesday May 16, 2018 5:30 PM – 7:30 PM
- Session title: Vector and Cell Engineering, Production or Manufacturing I
- Room: Stevens Salon C, D
Poster 338: Addressing Large-Scale Viral Vector Manufacturing Using an Optimized Pei-Based Transfection Process
Abstract: With the progress in developing new viral vector systems guided by safety, specificity and potency considerations, several gene and cell based therapies are now more than ever closer to being clinically approved and commercially available to treat genetic diseases. Viral vector delivery systems, of which mainly adeno-associated viruses (AAV) and lentiviruses are produced by transient transfection of mammalian producer HEK-293 cell lines. Virus vector production using the right transient transfection method is crucial to provide the flexibility and reproducibility that is needed to scale-up from initial process development to manufacturing of high-quality grade viral vectors.
Here, we describe an optimized PEI-based virus production process for high-yielding viral vector production, compatible with different cell culture adherent and suspension systems. We further demonstrate the robust viral vector production yields, as well as the adaptability and reliability of the PEI-based transient gene expression approach to efficiently manufacture GMP-grade viral vectors at a sufficiently large scale for more advanced clinical trials, and in fine to drive commercialization of therapeutic vectors.
Meet the delivery experts :
|Valerie Kedinger, PhD|
in vivo & GMP
|Patrick Erbacher, PhD|
|…||Julien Depollier, PhD|
Business Director Americas
This event will take place at the Hilton Chicago Hotel:
720 S Michigan Ave, Chicago, IL 60605, United States
Join us on social networks
We created a dedicated event on Facebook to allow you to discuss with other scientists about the ASGCT meeting or about your transfection experiments.
If you want to talk about this event (Facebook, Twitter, Google+, etc…), don’t forget to use the #ASGCT18 and follow the ASGCT news.